# Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

> **NCT05344209** · PHASE2 · RECRUITING · sponsor: **Vestre Viken Hospital Trust** · enrollment: 138 (estimated)

## Conditions studied

- Oncology
- NSCLC Stage IV
- NSCLC, Stage III

## Interventions

- **BIOLOGICAL:** UV1
- **DRUG:** Sagramostim
- **DRUG:** Anti-PD-1/PD-L1 treatment

## Key facts

- **NCT ID:** NCT05344209
- **Lead sponsor:** Vestre Viken Hospital Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-12
- **Primary completion:** 2025-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2023-11-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05344209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05344209, "Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05344209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*